These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 23996078)

  • 1. A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activity.
    Perera V; Gross AS; Forrest A; Landersdorfer CB; Xu H; Ait-Oudhia S; McLachlan AJ
    Drug Metab Dispos; 2013 Nov; 41(11):1957-66. PubMed ID: 23996078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics.
    Perera V; Gross AS; Xu H; McLachlan AJ
    J Pharm Pharmacol; 2011 Sep; 63(9):1161-8. PubMed ID: 21827488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma.
    Perera V; Gross AS; McLachlan AJ
    Biomed Chromatogr; 2010 Oct; 24(10):1136-44. PubMed ID: 20853468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of sodium tanshinone II A sulfonate on the activity of CYP1A2 in healthy volunteers.
    Chen Y; Tu JH; He YJ; Zhang W; Wang G; Tan ZR; Zhou G; Fan L; Zhou HH
    Xenobiotica; 2009 Jul; 39(7):508-13. PubMed ID: 19534587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effects of propafenone on the pharmacokinetics of caffeine in humans.
    Michaud V; Mouksassi MS; Labbé L; Bélanger PM; Ferron LA; Gilbert M; Grech-Bélanger O; Turgeon J
    Ther Drug Monit; 2006 Dec; 28(6):779-83. PubMed ID: 17164694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2?
    De Kesel PM; Lambert WE; Stove CP
    Clin Pharmacokinet; 2015 Jul; 54(7):771-81. PubMed ID: 25603821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two novel methods for the determination of CYP1A2 activity using the paraxanthine/caffeine ratio.
    Doude van Troostwijk LJ; Koopmans RP; Guchelaar HJ
    Fundam Clin Pharmacol; 2003 Jun; 17(3):355-62. PubMed ID: 12803575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omeprazole weakly inhibits CYP1A2 activity in man.
    Rost KL; Fuhr U; Thomsen T; Zaigler M; Brockmöller J; Bohnemeier H; Roots I
    Int J Clin Pharmacol Ther; 1999 Nov; 37(11):567-74. PubMed ID: 10584979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance.
    Spigset O; Hägg S; Söderström E; Dahlqvist R
    Eur J Clin Pharmacol; 1999 Feb; 54(12):943-6. PubMed ID: 10192755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2.
    Kinzig-Schippers M; Fuhr U; Zaigler M; Dammeyer J; Rüsing G; Labedzki A; Bulitta J; Sörgel F
    Clin Pharmacol Ther; 1999 Mar; 65(3):262-74. PubMed ID: 10096258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2.
    Labedzki A; Buters J; Jabrane W; Fuhr U
    Biochem Pharmacol; 2002 Jun; 63(12):2159-67. PubMed ID: 12110375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans.
    Bapiro TE; Sayi J; Hasler JA; Jande M; Rimoy G; Masselle A; Masimirembwa CM
    Eur J Clin Pharmacol; 2005 Nov; 61(10):755-61. PubMed ID: 16261361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The paraxanthine:caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the sample be obtained?
    Spigset O; Hägg S; Söderström E; Dahlqvist R
    Pharmacogenetics; 1999 Jun; 9(3):409-12. PubMed ID: 10471076
    [No Abstract]   [Full Text] [Related]  

  • 14. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking.
    Faber MS; Fuhr U
    Clin Pharmacol Ther; 2004 Aug; 76(2):178-84. PubMed ID: 15289794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance.
    Denaro CP; Wilson M; Jacob P; Benowitz NL
    Clin Pharmacol Ther; 1996 Mar; 59(3):284-96. PubMed ID: 8653991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine.
    Zandvliet AS; Huitema AD; de Jonge ME; den Hoed R; Sparidans RW; Hendriks VM; van den Brink W; van Ree JM; Beijnen JH
    Basic Clin Pharmacol Toxicol; 2005 Jan; 96(1):71-9. PubMed ID: 15667599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of a high-performance liquid chromatography assay for quantification of caffeine and paraxanthine in human serum in the context of CYP1A2 phenotyping.
    Koch JP; ten Tusscher GW; Koppe JG; Guchelaar HJ
    Biomed Chromatogr; 1999 Jun; 13(4):309-14. PubMed ID: 10416066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Determination of caffeine metabolite for the evaluation of N-acetyltransferase, CYP1A2 and xanthine oxidase activities].
    Lu JF; Yi T; Cao XM; Zhuo HT; Ling SS
    Yao Xue Xue Bao; 1997 Nov; 32(11):813-8. PubMed ID: 11596199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities.
    McQuilkin SH; Nierenberg DW; Bresnick E
    Cancer Epidemiol Biomarkers Prev; 1995 Mar; 4(2):139-46. PubMed ID: 7742721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of CYP1A2 activity: a focus on caffeine as a probe.
    Perera V; Gross AS; McLachlan AJ
    Curr Drug Metab; 2012 Jun; 13(5):667-78. PubMed ID: 22554278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.